Drug Information

General Information
Drug ID
DR00269
Drug Name
Mitoxantrone
Synonyms
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI); AN-584/42007670; DHAD; DHAQ; DHAQ (*Diacetate salt*); DHAQ HCl; Dihydroxyanthraquinone; Liposome Encapsulated Mitoxantrone (LEM); MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MIX; Misostol; Misostol (TN); Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantrone 2HCl; Mitoxantrone [INN]; Mitoxantronum; Mitoxantronum [INN-Latin]; Mitozantrone; Mitozantrone hydrochloride; Novantrone (TN); Novantrone(R) (mitoxantrone for injection concentrate)
Drug Type
Small molecular drug
Indication Non-hodgkin's lymphoma [ICD11: 2B33.5] Approved [1]
Metastatic breast cancer [ICD11: 2C6Y] Approved [1]
Acute myeloid leukemia [ICD11: 2A60] Approved [1]
Therapeutic Class
Analgesics
Structure
3D MOL 2D MOL
Formula
C22H28N4O6
Canonical SMILES
C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
InChI
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
InChIKey
KKZJGLLVHKMTCM-UHFFFAOYSA-N
CAS Number
CAS 65271-80-9
Pharmaceutical Properties Molecular Weight 444.5 Topological Polar Surface Area 163
Heavy Atom Count 32 Rotatable Bond Count 12
Hydrogen Bond Donor Count 8 Hydrogen Bond Acceptor Count 10
XLogP
1
PubChem CID
4212
PubChem SID
11111482 , 11111483 , 11335691 , 11360930 , 11364549 , 11367111 , 11369673 , 11372759 , 11374669 , 11377835 , 11406669 , 11406928 , 11461902 , 11466413 , 11467533 , 11484492 , 11486226 , 11488724 , 11491405 , 11492681 , 11495469 , 13376 , 142727 , 14710338 , 14857298 , 15047380 , 17417295 , 24769895 , 29223317 , 46394146 , 46504608 , 47216744 , 47365147 , 47440212 , 47440213 , 47515285 , 47662243 , 47736437 , 48035072 , 48035073 , 48184960 , 4873554 , 49698959 , 49870599 , 50111146 , 53790842 , 56352855 , 600874 , 7980008 , 8152633
ChEBI ID
ChEBI:50729
TTD Drug ID
D0R3JB
DT(s) Transporting This Drug ABCA3 Transporter Info ATP-binding cassette sub-family A member 3 Substrate [2]
BCRP Transporter Info Breast cancer resistance protein Substrate [3]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [4]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [5]
P-GP Transporter Info P-glycoprotein 1 Substrate [5]
Drug-Transporter Activity Data
Drug-Transporter Activity Data BCRP Transporter Info Km = 7 microM Spodoptera frugiperda (Sf9) cells-BCRP [3]
References
1 Mitoxantrone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33.
3 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
4 Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
5 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.